Bridge City Capital LLC decreased its position in shares of Phibro Animal Health Co. (NASDAQ:PAHC) by 3.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 96,274 shares of the company’s stock after selling 3,364 shares during the period. Bridge City Capital LLC owned 0.24% of Phibro Animal Health worth $2,780,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in the company. O Shaughnessy Asset Management LLC purchased a new position in shares of Phibro Animal Health in the second quarter valued at $49,000. Federated Hermes Inc. purchased a new stake in shares of Phibro Animal Health during the first quarter valued at $77,000. Sei Investments Co. purchased a new stake in shares of Phibro Animal Health during the first quarter valued at $202,000. M&T Bank Corp purchased a new stake in shares of Phibro Animal Health during the first quarter valued at $205,000. Finally, BNP Paribas Arbitrage SA boosted its stake in shares of Phibro Animal Health by 53.5% during the second quarter. BNP Paribas Arbitrage SA now owns 7,214 shares of the company’s stock valued at $208,000 after purchasing an additional 2,515 shares during the period. Hedge funds and other institutional investors own 52.74% of the company’s stock.
In related news, Director E Thomas Corcoran acquired 5,000 shares of the business’s stock in a transaction dated Monday, August 30th. The shares were purchased at an average price of $23.68 per share, for a total transaction of $118,400.00. Following the completion of the acquisition, the director now directly owns 20,000 shares in the company, valued at approximately $473,600. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 50.05% of the company’s stock.
Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Tuesday, August 24th. The company reported $0.32 EPS for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.01. Phibro Animal Health had a net margin of 6.53% and a return on equity of 23.68%. On average, sell-side analysts forecast that Phibro Animal Health Co. will post 1.3 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 22nd. Stockholders of record on Wednesday, September 1st will be issued a dividend of $0.12 per share. The ex-dividend date is Tuesday, August 31st. This represents a $0.48 annualized dividend and a dividend yield of 2.24%. Phibro Animal Health’s dividend payout ratio (DPR) is currently 38.71%.
Separately, Barclays lowered shares of Phibro Animal Health from an “equal weight” rating to an “underweight” rating and set a $23.00 target price for the company. in a research note on Wednesday, July 7th.
Phibro Animal Health Profile
Phibro Animal Health Corp. engages in the manufacture and supply of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops and markets antibacterial, nutritional specialty products, and vaccines.
Further Reading: Capital Gains
Want to see what other hedge funds are holding PAHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phibro Animal Health Co. (NASDAQ:PAHC).
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.